Pay in 4 interest-free payments of $7.26 Learn more
Ships within 48 hours · Estimated delivery Oct 9 - Oct 14
Tirzepatide targets two hormone receptorsGLP-1 and GIPwhile semaglutide targets only GLP-1, making tirzepatide a dual-action approach that clinical trials have shown may produce greater weight reduction for some patients
Primary outcome For the last 4 weeks of each intervention, on the studys AID system, the percentage of time in range was 74.2 (9.7) percentage points for semaglutide versus 69.4 (10.4) percentage points for placebo, a difference of 4.8 (7.6) percentage points ( P = 0.006
Texture:Bar
It also hasnt been published yet in a peer-reviewed journal
The benefits go beyond the number on the scale
